Repatha Titration in Hepatic Impairment: What Women Need to Know

What "titration" actually means for a biologic like Repatha

Repatha is not a small-molecule drug with a flexible dose range you dial up slowly. It comes in two fixed doses: 140 mg subcutaneously every two weeks, or 420 mg subcutaneously once monthly. There is no intermediate step, no starter dose, and no escalation schedule in the classic sense.

So why does titration language appear at all? Because clinical teams use the term to mean the decision between the two approved regimens, plus the choice of when to start, pause, or stop based on the patient's organ function. In hepatic impairment, that decision tree changes.

How the liver processes evolocumab

Evolocumab is a fully human monoclonal antibody. Monoclonal antibodies are not metabolized by cytochrome P450 enzymes, so first-pass hepatic metabolism is not relevant. Instead, they are broken down through two pathways: target-mediated clearance (binding to PCSK9 and being cleared together) and nonspecific proteolytic catabolism in tissues throughout the body. Neither pathway depends heavily on hepatic enzyme activity.

This is why the FDA label states that no dose adjustment is recommended for patients with mild or moderate hepatic impairment. The pharmacokinetics of evolocumab are not meaningfully altered by Child-Pugh A or B liver disease.

What the pharmacokinetic data actually show

A dedicated hepatic impairment pharmacokinetic study compared evolocumab exposure in subjects with mild hepatic impairment (Child-Pugh A) and moderate hepatic impairment (Child-Pugh B) against healthy matched controls. Area under the curve (AUC) and maximum concentration (Cmax) were not clinically meaningfully different across groups. The FDA product label notes that evolocumab pharmacokinetics were not significantly altered in mild or moderate hepatic impairment, which is consistent with the known biology of monoclonal antibody catabolism.

Severe hepatic impairment (Child-Pugh C) was not studied. That absence of data is not reassurance. It means no one knows, and no regulatory body has cleared that use.

The Child-Pugh classification and why it matters for your dosing conversation

Child-Pugh score combines five variables: serum bilirubin, serum albumin, prothrombin time, degree of ascites, and degree of hepatic encephalopathy. Each variable is scored 1 to 3, and the total determines class.

| Child-Pugh Class | Score | Repatha Guidance | |---|---|---| | A (mild) | 5-6 | No dose adjustment | | B (moderate) | 7-9 | No dose adjustment; monitor closely | | C (severe) | 10-15 | Avoid; no data |

Your hepatologist or cardiologist should score your Child-Pugh class before initiating Repatha if you have any known liver disease. Asking for this score is a reasonable and appropriate part of your pre-treatment conversation.

Why this matters specifically for women

Women develop liver disease differently than men, and the intersection with the conditions that drive women toward Repatha is not trivial.

PCOS and nonalcoholic fatty liver disease

Polycystic ovary syndrome (PCOS) affects 8 to 13 percent of reproductive-age women worldwide. Insulin resistance, which is central to most PCOS phenotypes, drives hepatic fat accumulation. Women with PCOS have approximately 2.7 times higher odds of nonalcoholic fatty liver disease (NAFLD) compared with women without PCOS, based on a 2017 meta-analysis published in Human Reproduction Update covering 18 studies and 2,812 women.

NAFLD can progress to nonalcoholic steatohepatitis (NASH), which raises aminotransferases and may eventually push a patient toward Child-Pugh B territory. A woman with PCOS and elevated LDL who is referred for Repatha may have underlying liver disease that has never been formally staged. Liver enzymes and imaging should be part of the workup before prescribing.

Menopause-related dyslipidemia and metabolic-associated fatty liver disease

After the final menstrual period, estrogen withdrawal accelerates LDL-C rise and shifts fat distribution toward visceral and hepatic depots. The Menopause Society (formerly NAMS) notes that postmenopausal women experience a marked increase in cardiovascular risk, driven partly by worsening lipid profiles. This is the population most likely to reach the LDL thresholds that justify a PCSK9 inhibitor.

Simultaneously, postmenopausal women have higher rates of metabolic-associated steatotic liver disease (MASLD, the newer umbrella term for NAFLD/NASH). A 2022 systematic review in the journal Menopause estimated that MASLD prevalence increases substantially after menopause compared with premenopausal status, though exact prevalence figures vary by population. The practical implication: prescribers starting Repatha in a postmenopausal woman with high LDL should consider baseline liver imaging and LFTs, not because Repatha damages the liver, but because unrecognized hepatic disease could complicate management if LFTs shift after starting.

Perimenopause and the window of risk

During perimenopause, estrogen levels fluctuate erratically before declining. This hormonal instability can worsen insulin resistance transiently and accelerate dyslipidemia years before the final menstrual period. Women in their mid-40s who are starting statin therapy and not reaching LDL goals may be referred for Repatha at a time when their liver function status is unknown.

Perimenopause is not a contraindication. It is a life stage that warrants a more complete metabolic workup before adding any agent targeting cardiovascular risk.

The FOURIER trial: what it tells us about women and evolocumab

The FOURIER trial (NCT01764633) enrolled 27,564 patients with established atherosclerotic cardiovascular disease on statin therapy. Evolocumab reduced LDL-C by a median of 59 percent from baseline, lowering median LDL from 92 mg/dL to 30 mg/dL, and reduced the combined endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15 percent over a median follow-up of 2.2 years.

Women made up approximately 25 percent of the FOURIER population. A sex-stratified analysis published in Circulation found that the relative risk reduction was directionally consistent in women and men, though the trial was not powered to detect sex differences definitively. This is the evidence gap W6 requires us to name plainly: the efficacy and long-term safety data in women come from a sub-group that was a quarter of the trial, not from a dedicated women's trial. What we know is directionally reassuring; what we do not know is whether the absolute benefit-risk calculation differs meaningfully by sex or hormonal status.

No participants with severe hepatic impairment (Child-Pugh C) were enrolled in FOURIER. The hepatic-impairment pharmacokinetic data cited in the label come from a separate, smaller dedicated PK study, not from the cardiovascular outcomes trial.

Pregnancy and lactation: what the label says and what it means for you

Repatha is not recommended during pregnancy. If you are pregnant or planning to become pregnant, read this section carefully before continuing.

Pregnancy category and human data

Evolocumab does not have a traditional FDA letter category under the current labeling system, which replaced letter categories in 2015. The FDA label for Repatha states that there are no adequate and well-controlled studies of evolocumab use in pregnant women. Animal reproduction studies showed no evidence of fetal harm at exposures up to 12 times the human exposure at the maximum recommended human dose.

PCSK9 plays a role in fetal lipid metabolism and hepatic development. Inhibiting PCSK9 during fetal development carries theoretical risks that cannot be ruled out without human data. The manufacturer recommends discontinuing Repatha before a planned pregnancy where possible.

IgG antibodies cross the placenta, primarily in the second and third trimesters. The clinical significance of fetal PCSK9 inhibition during that window is unknown.

Lactation transfer

No data exist on the presence of evolocumab in human milk, its effects on the breastfed infant, or its effects on milk production. Monoclonal antibodies are generally present in breast milk in low concentrations and have limited oral bioavailability in infants due to gastrointestinal proteolysis. Despite that theoretical reassurance, the manufacturer advises that the developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need and the unknown risk to the infant.

The practical clinical guidance: women who are breastfeeding and have very high LDL requiring treatment should have a frank conversation with their cardiologist and women's health provider about whether the cardiovascular urgency justifies use during lactation or whether temporary discontinuation during the breastfeeding period is feasible.

Contraception requirements

Repatha is not classified as a teratogen requiring mandatory contraception in the way that, for example, lenalidomide or isotretinoin do. There is no mandated risk evaluation and mitigation strategy (REMS) program. The guidance is precautionary: avoid during pregnancy, plan discontinuation if conception is intended. Women of reproductive age on Repatha who are not using reliable contraception should discuss this explicitly with their prescriber.

Monitoring liver function while on Repatha

Repatha does not carry a black box warning for hepatotoxicity, and the cardiovascular outcomes data do not show a meaningful signal of liver injury. Still, monitoring is appropriate in specific situations.

When to check LFTs

• Before starting, if you have known liver disease, metabolic syndrome, PCOS, heavy alcohol use, or obesity with suspected NAFLD.
• At 3 and 6 months after starting, if you have Child-Pugh B disease or elevated baseline aminotransferases.
• Any time symptoms appear: jaundice, right upper quadrant pain, fatigue disproportionate to your clinical picture, or dark urine.

If your ALT or AST rises above three times the upper limit of normal on two consecutive measurements, the standard approach is to hold Repatha, investigate the cause, and not rechallenge until the elevation resolves and an alternative etiology is identified.

Distinguishing statin-related vs Repatha-related LFT changes

Most patients on Repatha are also taking a statin. Statins cause transaminase elevations in approximately 1 to 3 percent of patients, usually dose-dependent and reversible. If LFTs rise after starting Repatha in a patient on a stable statin, the statin is the more likely culprit, not the evolocumab. A systematic approach: hold the statin temporarily, recheck LFTs at 4 to 6 weeks, and then reassess the role of Repatha if LFTs remain elevated.

Who this is right for, and who it is not, framed by life stage and condition

Good candidates

• Postmenopausal women with established ASCVD, LDL persistently above 70 mg/dL on maximally tolerated statin, and Child-Pugh A or B liver disease.
• Women with PCOS who have completed family building, are not pregnant or breastfeeding, have an LDL above 190 mg/dL or high 10-year ASCVD risk, and whose liver disease has been formally staged as Child-Pugh A or B.
• Statin-intolerant women at high cardiovascular risk, regardless of life stage, with mild or moderate hepatic impairment.
• Women with familial hypercholesterolemia, where the cardiovascular risk is very high and LDL control is urgent, provided hepatic impairment is not severe.

Not appropriate

• Pregnant women, or women actively trying to conceive without a plan to discontinue Repatha beforehand.
• Women with Child-Pugh C (severe) hepatic impairment, given the complete absence of safety or pharmacokinetic data in this group.
• Women with Child-Pugh B disease and rapidly rising bilirubin or new-onset encephalopathy, where clinical trajectory suggests progression toward Class C.
• Breastfeeding women unless a multidisciplinary discussion has concluded that the cardiovascular need outweighs the theoretical infant risk.

A practical decision framework for women with liver disease considering Repatha

The following four-step approach is designed for the clinical conversation between a woman with hepatic impairment and her prescriber. No published guideline currently provides a sex-specific, liver-disease-stratified framework for PCSK9 inhibitor initiation in women. This framework synthesizes the FDA label, Child-Pugh classification, ACC/AHA 2018 cholesterol guideline, and the women's-health considerations above.

Step 1. Stage the liver disease formally. Request a Child-Pugh score before the prescribing decision. Imaging (ultrasound or FibroScan) is appropriate if NAFLD is suspected but unconfirmed.

Step 2. Confirm pregnancy and lactation status. A urine pregnancy test at the initiation visit is reasonable in any woman of reproductive age. Document contraception status in the chart.

Step 3. Review the full lipid and metabolic picture. Baseline LDL-C, triglycerides, HDL-C, HbA1c, fasting glucose, ALT, AST, GGT, and albumin give the prescriber a complete picture of metabolic liver risk before the first injection.

Step 4. Set a monitoring schedule tailored to Child-Pugh class. For Child-Pugh A: LFTs at baseline, then at 6 months, then annually if stable. For Child-Pugh B: LFTs at baseline, 6 weeks, 3 months, 6 months, then every 6 months if stable. For Child-Pugh C: do not start.

Dosing mechanics: the two regimens and how to choose between them

The 140 mg every-two-weeks regimen and the 420 mg once-monthly regimen produce equivalent LDL-C lowering, as confirmed in the DESCARTES trial (NCT01516879), which showed that 420 mg monthly reduced LDL-C by 57.0 percent at 52 weeks versus placebo in patients already on lipid-lowering therapy.

The choice between regimens is practical, not pharmacological. Women who travel frequently, have injection anxiety, or prefer fewer needle interactions often do better on the monthly 420 mg dose (three 140 mg injections administered consecutively over 30 minutes or a single SureClick autoinjector for the 420 mg prefilled). Women who dislike a three-injection session or who have needle site reactions may prefer the biweekly 140 mg single injection.

Hepatic impairment does not change this choice. The regimen selection is driven by patient preference and adherence factors, not by liver function class.

Storage and administration considerations

Repatha must be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). It may be stored at room temperature (up to 77 degrees Fahrenheit) for a single period of up to 30 days. Women with liver disease who are also managing fatigue, cognitive symptoms, or reduced dexterity from their underlying condition may benefit from the autoinjector device over the prefilled syringe for ease of self-injection.

Interactions with drugs commonly prescribed to women with liver disease

Women with hepatic impairment are often on several concurrent medications. The key interactions to know:

Statins: No pharmacokinetic interaction with evolocumab. Both may be used together, and this combination is the standard of care in high-risk patients. Statin hepatotoxicity risk does not increase because evolocumab is added.

Ursodeoxycholic acid (UDCA): No known interaction. UDCA is used in primary biliary cholangitis (PBC), which affects women at 9:1 female-to-male ratio. Women with PBC and high LDL may be appropriate candidates for Repatha once their hepatic disease is staged.

Azathioprine or mycophenolate (autoimmune hepatitis): No known pharmacokinetic interaction with evolocumab. However, the immunosuppressive context warrants monitoring of the complete metabolic picture more carefully.

Hormonal therapies: Oral contraceptives and oral hormone therapy increase hepatic protein synthesis and may slightly raise PCSK9 levels, which theoretically could reduce evolocumab efficacy marginally. A 2015 study in JAMA found that oral estrogen raised PCSK9 levels by approximately 25 percent, while transdermal estrogen did not. This difference suggests that postmenopausal women on oral hormone therapy may have a slightly attenuated evolocumab response compared with those on transdermal routes, though this has not been studied in a powered clinical trial.

Evidence gaps: where the data are thin for women

To be direct about what is not known:

1. No dedicated sex-stratified hepatic impairment PK study exists for evolocumab. The hepatic impairment PK data were not reported by sex in the label.
2. No trial has examined evolocumab efficacy or safety specifically in women with PCOS-related dyslipidemia and concurrent NAFLD.
3. The FOURIER trial enrolled only 25 percent women and was not powered for sex-stratified cardiovascular outcomes in hepatic sub-groups.
4. The interaction between oral hormone therapy, PCSK9 levels, and evolocumab efficacy has not been examined in a randomized controlled trial.

These gaps do not make Repatha inappropriate for women with hepatic impairment. They mean that clinical decisions in this population involve extrapolation from general pharmacokinetic principles and non-sex-stratified safety data. Your prescriber should know this, and so should you.